By Adriano Marchese
McKesson has agreed to acquire a controlling interest in eye-health company PRISM Vision Holdings for $850 million as it looks to develop a retinal and ophthalmology platform.
The diversified healthcare services company said Tuesday it will acquire an 80% stake in the company, while PRISM Vision physicians will continue to retain a 20% interest in the business.
McKesson chief executive, Brian Tyler, said the acquisition strengthens its community practice and specialty solutions, while building a platform to serve a high-growth area of retina and ophthalmology.
"We intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners and patients," Tyler said.
McKesson expects PRISM Vision to add about 20 cents to 30 cents to its adjusted earnings per share in the first 12 months following the close of the transaction, and then to be between 65 cents and 75 cents accretive by the end of the third year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 04, 2025 08:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。